{"id":"flu-atg","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Serum sickness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATG (anti-thymocyte globulin) works by binding to and eliminating T cells, which are central mediators of immune rejection and autoimmune disease. The polyclonal antibody preparation targets multiple epitopes on T-cell surfaces, leading to complement-dependent and antibody-dependent cellular cytotoxicity. This profound T-cell depletion creates an immunosuppressive state useful in transplantation and severe autoimmune conditions.","oneSentence":"Flu-ATG is an anti-thymocyte globulin derived from immunized rabbits that depletes T lymphocytes to suppress immune-mediated rejection and autoimmune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:52.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Aplastic anemia"},{"name":"Acute graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT07249346","phase":"PHASE2","title":"Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hannah Choe, MD","startDate":"2026-06-01","conditions":"Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia","enrollment":124},{"nctId":"NCT02828592","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2016-09-09","conditions":"Severe Aplastic Anemia","enrollment":20},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT04558736","phase":"PHASE2","title":"Haploidentical HCT for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-01-21","conditions":"Aplastic Anemia, Bone Marrow Failure Syndrome","enrollment":21},{"nctId":"NCT06674382","phase":"NA","title":"Haplo-HSCT for Myelofibrosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Myelofibrosis","enrollment":39},{"nctId":"NCT06946602","phase":"NA","title":"Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-20","conditions":"AML, Elderly","enrollment":307},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT03367546","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-07-02","conditions":"Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders","enrollment":5},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT06069180","phase":"PHASE4","title":"The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-11-15","conditions":"Severe Aplastic Anemia","enrollment":160},{"nctId":"NCT05629260","phase":"","title":"The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-12-01","conditions":"Hematological Malignancy","enrollment":300},{"nctId":"NCT05921318","phase":"","title":"Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-06-01","conditions":"Hematologic Malignancy, Stem Cell Transplant Complications","enrollment":20},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT03852407","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","status":"RECRUITING","sponsor":"University of Liege","startDate":"2019-02-04","conditions":"Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission","enrollment":114},{"nctId":"NCT05528354","phase":"EARLY_PHASE1","title":"Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2022-06-02","conditions":"Hematopoietic Stem Cell Transplantation, TP53","enrollment":58},{"nctId":"NCT02833805","phase":"PHASE2","title":"NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09","conditions":"Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure","enrollment":21},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":"Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection","enrollment":256},{"nctId":"NCT02181478","phase":"EARLY_PHASE1","title":"Intra-Osseous Co-Transplant of UCB and hMSC","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-07-22","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":6},{"nctId":"NCT00176852","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Hemoglobinopathy","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-06","conditions":"Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia","enrollment":22},{"nctId":"NCT01037764","phase":"PHASE2","title":"Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Acute Lymphoid Leukemia","enrollment":100},{"nctId":"NCT01565616","phase":"PHASE2","title":"Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-03","conditions":"Sickle Cell Disease","enrollment":22},{"nctId":"NCT02127892","phase":"PHASE1, PHASE2","title":"SCID Bu/Flu/ATG Study With T Cell Depletion","status":"TERMINATED","sponsor":"Neena Kapoor, M.D.","startDate":"2007-01-02","conditions":"Severe Combined Immunodeficiency","enrollment":9},{"nctId":"NCT03190733","phase":"PHASE4","title":"A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2017-08-30","conditions":"Chronic Graft-versus-host-disease, Leukemia Relapse","enrollment":192},{"nctId":"NCT03171831","phase":"PHASE4","title":"Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2017-04-01","conditions":"Thalassemia Major","enrollment":30},{"nctId":"NCT01455506","phase":"PHASE1","title":"PRO#0118: Decitabine Plus Mini Flu-Bu","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2009-05","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":20},{"nctId":"NCT00894049","phase":"PHASE2","title":"A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2002-11","conditions":"Allograft, Allogeneic Cell Transplantaion, Hematological Malignancy","enrollment":148},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT01145976","phase":"PHASE3","title":"Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia","status":"UNKNOWN","sponsor":"Cooperative Study Group A for Hematology","startDate":"2010-03","conditions":"Aplastic Anemia","enrollment":98},{"nctId":"NCT00882323","phase":"PHASE2","title":"Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)","status":"UNKNOWN","sponsor":"The Korean Society of Pediatric Hematology Oncology","startDate":"2008-11","conditions":"Aplastic Anemia","enrollment":33},{"nctId":"NCT00774527","phase":"PHASE3","title":"Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2003-03","conditions":"Bone Marrow Failure Syndromes","enrollment":82},{"nctId":"NCT00275678","phase":"PHASE3","title":"Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2003-11","conditions":"Blood Stem Cell Transplant","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fludarabine","Thymoglobulin"],"phase":"phase_3","status":"active","brandName":"Flu-ATG","genericName":"Flu-ATG","companyName":"Cooperative Study Group A for Hematology","companyId":"cooperative-study-group-a-for-hematology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flu-ATG is an anti-thymocyte globulin derived from immunized rabbits that depletes T lymphocytes to suppress immune-mediated rejection and autoimmune responses. Used for Aplastic anemia, Acute graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}